Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
30 April 2010 Proposal to list ABM Pharma Limited’s brand of cephalexin 500 mg capsules PHARMAC is seeking feedback on a proposal to fund ABM Pharma Limited’s brand of cephalexin monohydrate 500 mg capsules (Cephalexin ABM) from 1 September 2010. In summary, this proposal would result in: § The Cephalexin ABM brand of cephalexin monohydrate 500 mg capsules being listed in section B and Part II of Section H of the of the Pharmaceutical Schedule from 1 September 2010; and § Subsidy and delisting protection for Cephalexin ABM until 1 July 2013. Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 14 May 2010 to: Greg Williams Therapeutic Group Manager PHARMAC PO Box 10 254 Wellington 6143 Email: [email protected] Fax: 04 460 4995 All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. Details of the proposal PHARMAC and AMB Pharma Limited have entered into a provisional agreement relating to the supply of cephalexin monohydrate 500 mg capsules (Cephalexin ABM). Cephalexin ABM would be listed, in the Infections – Agents for Systemic Use therapeutic group, in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 September 2010 at the following prices and subsidies (ex manufacturer and exclusive of GST): Chemical Presentation Brand Pack size Price and subsidy Cephalexin monohydrate Capsules, 500 mg Cephalexin ABM 20 $8.90 Cephalexin ABM would have subsidy and delisting protection until 1 July 2013. A350455 Page 1 of 2 Background PHARMAC currently funds cephalexin granules for oral liquid 125 mg per 5 ml and 250 mg per 5 ml without restriction. This proposal would secure supply of a cephalexin capsule until at least 1 July 2013. The indicated daily adult dose of cephalexin is between one and four grams daily. Whilst this dosage can be provided by the oral liquid the capsule formulation would be a more acceptable dosage form. Cephalexin is a first generation oral cephalosporin indicated for the treatment of the following infections when caused by susceptible strains of microorganisms: · · · · · · · Bacterial sinusitis Respiratory tract infections caused Otitis media Skin and skin-structure infections. Bone infections Genitourinary tract infections, Dental infections. A350455 - T10-435